Fecal microbiota transplantation as novel therapy in gastroenterology : A systematic review

Show simple item record

dc.contributor.author Rossen, Noortje G.
dc.contributor.author MacDonald, John K.
dc.contributor.author de Vries, Elisabeth M.
dc.contributor.author D'Haens, Geert R.
dc.contributor.author de Vos, Willem M.
dc.contributor.author Zoetendal, Erwin G.
dc.contributor.author Ponsioen, Cyriel Y.
dc.date.accessioned 2016-06-16T08:21:01Z
dc.date.available 2016-06-16T08:21:01Z
dc.date.issued 2015-05-07
dc.identifier.citation Rossen , N G , MacDonald , J K , de Vries , E M , D'Haens , G R , de Vos , W M , Zoetendal , E G & Ponsioen , C Y 2015 , ' Fecal microbiota transplantation as novel therapy in gastroenterology : A systematic review ' , World Journal of Gastroenterology , vol. 21 , no. 17 , pp. 5359-5371 . https://doi.org/10.3748/wjg.v21.i17.5359
dc.identifier.other PURE: 49515927
dc.identifier.other PURE UUID: 300f49fe-5896-4342-a687-a92be235f31e
dc.identifier.other WOS: 000353774100028
dc.identifier.other Scopus: 84928983066
dc.identifier.uri http://hdl.handle.net/10138/163944
dc.description.abstract AIM: To study the clinical efficacy and safety of Fecal microbiota transplantation (FMT). We systematically reviewed FMT used as clinical therapy. METHODS: We searched MEDLINE, EMBASE, the Cochrane Library and Conference proceedings from inception to July, 2013. Treatment effect of FMT was calculated as the percentage of patients who achieved clinical improvement per patient category, on an intention-to-treat basis. RESULTS: We included 45 studies; 34 on Clostridium difficile-infection (CDI), 7 on inflammatory bowel disease, 1 on metabolic syndrome, 1 on constipation, 1 on pouchitis and 1 on irritable bowel syndrome (IBS). In CDI 90% resolution of diarrhea in 33 case series (n = 867) was reported, and 94% resolution of diarrhea after repeated FMT in a randomized controlled trial (RCT) (n = 16). In ulcerative colitis (UC) remission rates of 0% to 68% were found (n = 106). In Crohn's disease (CD) (n = 6), no benefit was observed. In IBS, 70% improvement of symptoms was found (n = 13). 100% Reversal of symptoms was observed in constipation (n = 3). In pouchitis, none of the patients (n = 8) achieved remission. One RCT showed significant improvement of insulin sensitivity in metabolic syndrome (n = 10). Serious adverse events were rare. CONCLUSION: FMT is highly effective in CDI, and holds promise in UC. As for CD, chronic constipation, pouchitis and IBS data are too limited to draw conclusions. FMT increases insulin sensitivity in metabolic syndrome. en
dc.format.extent 13
dc.language.iso eng
dc.relation.ispartof World Journal of Gastroenterology
dc.rights cc_by_nc
dc.rights.uri info:eu-repo/semantics/openAccess
dc.subject Fecal microbiota transplantation
dc.subject Microbiota
dc.subject Clostridium difficile infection
dc.subject Inflammatory bowel disease
dc.subject Metabolic syndrome
dc.subject TERM-FOLLOW-UP
dc.subject CASE SERIES
dc.subject BOWEL-FLORA
dc.subject INFECTION
dc.subject DIARRHEA
dc.subject COLONOSCOPY
dc.subject 3111 Biomedicine
dc.title Fecal microbiota transplantation as novel therapy in gastroenterology : A systematic review en
dc.type Review Article
dc.contributor.organization Departments of Faculty of Veterinary Medicine
dc.contributor.organization Willem Meindert Vos de / Principal Investigator
dc.contributor.organization Veterinary Biosciences
dc.contributor.organization Veterinary Microbiology and Epidemiology
dc.contributor.organization Department of Bacteriology and Immunology
dc.contributor.organization Medicum
dc.contributor.organization de Vos & Salonen group
dc.description.reviewstatus Peer reviewed
dc.relation.doi https://doi.org/10.3748/wjg.v21.i17.5359
dc.relation.issn 1007-9327
dc.rights.accesslevel openAccess
dc.type.version publishedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
WJG_21_5359.pdf 1.002Mb PDF View/Open

This item appears in the following Collection(s)

Show simple item record